Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.32 |
| ▸ | JMJD6 | Q6NYC1 | 4/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30338957 | 0.84 | MGLL (0.35) | MGLL | |
| Trifluoroacetic Acid SCHEMBL25296943 | 0.72 | RAB9A (0.33) | SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL30338989 | 0.72 | TRPA1 (0.34) | — | |
| Trifluoroacetic Acid SCHEMBL30339598 | 0.72 | DPP4 (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL25297194 | 0.72 | POLB (0.34) | SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL29048254 | 0.71 | GPR6 (0.33) | CCR2 | |
| Trifluoroacetic Acid SCHEMBL25296509 | 0.70 | FFAR4 (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL30338646 | 0.69 | CHRNB2 (0.33) | — | |
| Trifluoroacetic Acid SCHEMBL29966503 | 0.69 | JAK2 (0.32) | SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL18921382 | 0.69 | JAK2 (0.32) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| EP-4157835-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | MGLL 4649/4885DDB1 2916/4885CRBN 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.